Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00364871 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of Combination Therapy to Treat Uncomplicated Obesity
A Phase 2 study, sponsored by Orexigen Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 410
- Enrollment target
NCT00364871 is a Phase 2 study that has completed, run by Orexigen Therapeutics. The registered enrollment target is 410 participants.
The verdict
NCT00364871, a Phase 2 study, has completed, sponsored by Orexigen Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 410 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy and safety of 3 combinations of naltrexone and bupropion SR compared to naltrexone alone, bupropion SR alone or placebo.
Interventions
- DRUG naltrexone and bupropion SR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 410 participants |
| Start Date | 2005-04 |
| Est. Completion | 2007-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00364871
The ClinicalTrials.gov registry entry for NCT00364871 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 410 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Orexigen Therapeutics, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which naltrexone and bupropion SR is the first listed.
NCT00364871 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00364871 about?
NCT00364871 is a clinical study titled "Efficacy and Safety Study of Combination Therapy to Treat Uncomplicated Obesity". The purpose of this study is to determine the efficacy and safety of 3 combinations of naltrexone and bupropion SR compared to naltrexone alone, bupropion SR alone or placebo.
What is the current status of trial NCT00364871?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 410 participants. The study started on 2005-04. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00364871?
The interventions under investigation include: naltrexone and bupropion SR (DRUG).
Who is sponsoring clinical trial NCT00364871?
This trial is sponsored by Orexigen Therapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.